Summary: What the Pipeline Holds

Some areas of drug development have moved further in the past five years than in the prior twenty. Others have barely moved at all.

Pain has a genuinely new drug class for the first time in two decades. Suzetrigine blocks pain signals in peripheral nerves without acting on the central nervous system: no addiction risk, no sedation. It costs $15.50 per pill, roughly $420 per week. Phase 3 trials for diabetic peripheral neuropathy are underway.

Cholesterol management may shift from daily pills to twice-yearly injections. Inclisiran reduces LDL by roughly 50%, sustained over six years, administered at a doctor’s office every six months. For statin-intolerant patients, that change is significant. Cardiovascular outcomes data from the ORION-4 trial is expected by mid-2026. Cost: $6,500 per year.

The SGLT2 inhibitors (empagliflozin, dapagliflozin) may be the most consequential drug class expansion of the decade for older adults. Originally for diabetes, they now carry FDA approvals for heart failure and chronic kidney disease regardless of diabetes status. Heart failure hospitalizations dropped roughly 25%. Kidney disease progression slowed significantly. Finerenone adds a second protective layer for diabetic kidney disease through a different pathway. Current guidelines recommend using both together, creating a three-drug foundation that protects the organs diabetes quietly destroys.

GLP-1 drugs continue expanding their reach: cardiovascular disease, kidney protection, sleep apnea. A single injection may eventually replace two or three separate prescriptions, directly addressing polypharmacy. Semaglutide’s negotiated Medicare price for 2027 is $274, down from over $1,000. Next-generation triple agonists like retatrutide showed weight loss of up to 24% in Phase 2, with Phase 3 years away.

Factor XI inhibitors promise anticoagulation that separates clot prevention from bleeding risk, potentially transforming treatment for atrial fibrillation patients over 65 who currently face difficult trade-offs with warfarin and direct oral anticoagulants. Phase 3 trials reported in late 2025 showed significant stroke reduction with lower bleeding rates. FDA decisions are expected in 2026.

For osteoporosis, romosozumab builds bone rather than merely slowing loss. For COPD, dupilumab became the first biologic therapy to reduce exacerbations in moderate-to-severe disease. For Alzheimer’s, the amyloid-targeting drugs are first-generation; anti-tau therapies in trials could address pathology the current drugs miss.

The areas where older adults need the most help are often where the pipeline is emptiest. Sarcopenia, the progressive muscle loss that underlies frailty, falls, and functional decline, has no approved drug. Not one. The pharmaceutical industry has largely walked away because clinical endpoints are hard to define and the regulatory pathway is uncertain. Meanwhile, muscle loss remains one of the strongest predictors of whether an 80-year-old lives independently or in a nursing home.

The gap between a treatment’s efficacy in a trial and its availability at the kitchen table persists across every condition. A drug that works in a study of 3,000 patients means nothing to the person whose insurance denies the prior authorization or whose nearest infusion center is 90 miles away. The pipeline is richer than it was five years ago. Whether it reaches the people who need it most depends on systems that no molecule can fix.